Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

CMPS, Trump and Compass Pathways

Digest more
Top News
Overview
Impacts
Barchart on MSN · 22h
Trump sends Compass Pathways stock soaring as he backs psychedelics. Should you buy CMPS here?
Compass Pathways (CMPS) shares printed a new year-to-date high on April 20 after President Donald Trump signed a landmark executive order to accelerate the approval and research of “psychedelic” medicines.

Continue reading

 · 23h · on MSN
Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use
Blockonomi · 1d
COMPASS Pathways (CMPS) Stock Soars 25% on Trump’s Psychedelics Research Order
 · 1d
Trump Fast-Tracks Psychedelic Medicine After Hearing Antidepressant Effectiveness Data: “That’s Not Great”
Podcast host Joe Rogan says a text message to President Trump resulted in an executive order signed Saturday morning to allow the use of psychedelic drugs to treat mental health disorders.

Continue reading

 · 13h
Peoria veteran hails Trump's push for accelerating psychedelic drug research as ‘life-changing’
 · 20h
Trump Signed a Psychedelic Drugs Order—and These 4 Stocks Surged
 · 1d
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Trump also said the government would allocate $50 million for federal research into ibogaine.

Continue reading

 · 16h
What is ibogaine, the psychedelic drug endorsed by Joe Rogan?
 · 19h
What to know about psychedelics treating mental health disorders amid Trump's EO
1don MSN

Why Compass Pathways Stock Rocketed 40% Today

Compass Pathways may be the first to benefit from an accelerated approval process.
Investor's Business Daily on MSN
21h

How Trump sent psychedelics-tied Compass Pathways and others flying

Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs.
1h

Compass Pathways: Red Hot Psychedelic Market For Pioneer With Near Term Psychedelic Filing In TRD

Towards that end in 2018, it received FDA's Breakthrough Therapy designation for COMP360 in the treatment of TRD. In 11/2021 it announced positive results from its phase 2b trial which was written up in an 11/2022 article in NEJM. In 2025, it commenced a pivotal trial program for COMP360. It consisted of:
Barron's
34m

COMPASS Pathways PLC ADR

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by ...
1d

Stock Movers: Eli Lilly, Compass Pathways, Fermi

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
AOL
2mon

Why Did Compass Pathways Stock Rocket Higher Today?

It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the company received breakthrough therapy designation from ...
28d

Compass Pathways Stock Falls on Widened 4Q Loss

Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.
1d

Stock Movers: Alphabet, Adobe, Compass Pathways

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
1d

Why COMPASS Pathways (CMPS) Is Up 15.4% After Psilocybin Phase 3 Wins And FDA Filing Momentum

Earlier this month, COMPASS Pathways welcomed a White House Executive Order aimed at accelerating treatments for serious mental illness, as it reported two positive phase 3 trials of its COMP360 synthetic psilocybin in treatment-resistant depression and advanced a rolling FDA submission.

Related topics

Trump
White House
CMPS
Coinbase
  • Privacy
  • Terms